https://digital.nhs.uk/data-and-information/publications/statistical/cervical-screening-programme<\/a><\/p> <\/p>
As part of the delivery of the General Practitioner Five Year Forward View, the National Health Service is investing more than £258 million to improve access to general practice. Patients are now benefitting from improved access to all routine appointments (including cervical screening), at evening and/or weekends.<\/p>
<\/p>
The NHS Cervical Cancer screening programme saves an estimated 5,000 lives a year by detecting abnormalities of the cervix early and referring women for effective treatment.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-03-21T16:22:48.23Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cervical Cancer: Screening"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 February 2019 to Question 223982 on Cervical Cancer: Screening, if he will make it his policy to (a) require CCGs to monitor and report to him on the availability of cervical screening appointments at GP surgeries and (b) request the information necessary to allow him to monitor regularly the rates of attendance for cervical screening appointments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3930", "label" : {"_value" : "Biography information for Caroline Lucas"}
}
, "tablingMemberConstituency" : {"_value" : "Brighton, Pavilion"}
, "tablingMemberPrinted" : [{"_value" : "Caroline Lucas"}
], "uin" : "231979"}
, {"_about" : "http://data.parliament.uk/resources/1088277", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1088277/answer", "answerText" : {"_value" : "
NHS England\u2019s focus on improving the physical needs of this patient population have resulted in the development of a dedicated medicine improvement programme for those in an immigration removal centre (IRC).<\/p>
<\/p>
The programme aims to improve the optimisation of medicines for people in immigration removal centres and has been underpinned by specific professional medicines optimisation standards published in partnership with the Royal Pharmaceutical Society (2017).<\/p>
<\/p>
The programme aims to improve the optimisation of medicines for people in IRCs to deliver:<\/p>
<\/p>
- A clear understanding of current provision of pharmacy services, including on-site services, and medicines handling and use in IRCs;<\/p>
- An audit of the medicines standards in all IRCs to support quality improvement in pharmacy services and medicines optimisation;<\/p>
- Identification of key improvement priorities for each IRC based on the gap analysis between provision and expected standards;<\/p>
- Introduction by providers of policies and an IT-based risk assessment tools to enable as many detainees as possible to self-administer their medicines;<\/p>
- Provide medicines in an environment where people can maintain confidentiality and access support from pharmacy staff about their medicines; and<\/p>
- Improve continuity of medicines on admission through more effective electronic recording during their period of detention in IRCs as well as on their release and transfer or deportation.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-03-18", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-03-18T14:19:34.24Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Migrants: Detainees"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps are taken to ensure that people in immigration removal centres have uninterrupted access to prescribed medication.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4571", "label" : {"_value" : "Biography information for Gill Furniss"}
}
, "tablingMemberConstituency" : {"_value" : "Sheffield, Brightside and Hillsborough"}
, "tablingMemberPrinted" : [{"_value" : "Gill Furniss"}
], "uin" : "232076"}
, {"_about" : "http://data.parliament.uk/resources/1088329", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1088329/answer", "answerText" : {"_value" : "
The Department of Health and Social Care is working closely with the Department for Education to improve the mental health of undergraduate students. Our joint document, \u2018Transforming children and young people\u2019s mental health provision: a green paper\u2019, includes a commitment to build a new national strategic partnership with key stakeholders to improve the mental health of 16 to 25 year olds in schools, colleges and universities, by facilitating coordinated action, experimentation and robust evaluation on leadership, prevention and improved data collection.<\/p>
To support this, the NHS Long Term Plan commits to a comprehensive expansion of mental health services, including a new approach to mental health services for people aged 18-25, supporting transitions to college and to adulthood, with services being adapted to create a comprehensive offer for 0-25-year olds.<\/p>
NHS England is working closely with Universities UK through the Mental Health in Higher Education programme to build the capability and capacity of universities to improve student welfare services and improve access to mental health services for the student population, including focusing on suicide reduction, and improving access to psychological therapies to support treat students suffering from stress and anxiety.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-03-18", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-03-18T14:21:04.897Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Health: Students"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps the Government is taking to reduce the prevelance of (a) stress, (b) loneliness, (c) anxiety, and (d) substance misuse among undergraduate students.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/534", "label" : {"_value" : "Biography information for Chris Ruane"}
}
, "tablingMemberConstituency" : {"_value" : "Vale of Clwyd"}
, "tablingMemberPrinted" : [{"_value" : "Chris Ruane"}
], "uin" : "231917"}
, {"_about" : "http://data.parliament.uk/resources/1088345", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1088345/answer", "answerText" : {"_value" : "
NHS England does not hold information on the number of National Health Service trusts in England that have outsourced cancer treatment services.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2019-03-18", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-03-18T16:25:54.653Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent estimate his Department has made of the number of NHS trusts in England that have outsourced cancer treatment services, in part or in whole, to private sector providers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/308", "label" : {"_value" : "Biography information for Mr Jim Cunningham"}
}
, "tablingMemberConstituency" : {"_value" : "Coventry South"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jim Cunningham"}
], "uin" : "231900"}
, {"_about" : "http://data.parliament.uk/resources/1088401", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1088401/answer", "answerText" : {"_value" : "
In April 2018, strengthened regulatory measures for valproate were introduced following a European-wide review of the latest evidence on harms from valproate exposure during pregnancy, including congenital anomalies and neurodevelopmental disorders including autism in children. These measures include the valproate Pregnancy Prevention Programme, the goal of which is to rapidly reduce and eventually eliminate pregnancies exposed to valproate.<\/p>
<\/p>
The Medicines and Healthcare products Regulatory Agency (MHRA) is monitoring the impact of, and adherence to, the strengthened regulatory recommendations for valproate including the Pregnancy Prevention Programme, using research studies and routinely collected healthcare data. These include data from the Clinical Practice Research Datalink, national databases in England (NHS Business Services Authority and NHS Digital), Scotland (Information Services Division), and Northern Ireland (Health and Social Care Northern Ireland) linking community drug dispensing and maternity services data where these are available. The MHRA is also accessing data on valproate from clinical audits run by healthcare professional organisations, and information on patients\u2019 experience of introduction of the strengthened regulatory measures via surveys conducted by charitable organisations and patient groups.<\/p>
<\/p>
Monitoring of prescribing of valproate has shown a slow, continued decline in women of childbearing age. Data show variability in levels of prescribing of valproate to women of childbearing age across different clinical commissioning groups in England. The current monitoring methods used by the MHRA do not enable comprehensive monitoring of compliance at the prescriber or patient level. It is therefore not possible to estimate the number of healthcare professionals who are not complying with all aspects of the Pregnancy Prevention Programme. Surveys of patient experiences have shown some evidence of non-compliance amongst healthcare professionals with the valproate Pregnancy Prevention Programme. Actions are being taken by the relevant professional regulators to follow up and address this.<\/p>
<\/p>
The recent European review of valproate in pregnancy considered a possible association between birth defects and persistent developmental disorders associated with paternal valproate treatment at the time of conception. The review concluded that there was insufficient evidence at present to establish such a link. A retrospective observational study is to be undertaken to further investigate this issue for which a study protocol is currently being agreed by the European Medicines Agency.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "232044"}
, {"_value" : "232045"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-03-21T12:14:16.81Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pregnancy: Sodium Valproate"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the valproate pregnancy prevention programme in reducing the number of children born with birth defects and persistent developmental disorders.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4436", "label" : {"_value" : "Biography information for Cat Smith"}
}
, "tablingMemberConstituency" : {"_value" : "Lancaster and Fleetwood"}
, "tablingMemberPrinted" : [{"_value" : "Cat Smith"}
], "uin" : "232043"}
, {"_about" : "http://data.parliament.uk/resources/1088402", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1088402/answer", "answerText" : {"_value" : "
In April 2018, strengthened regulatory measures for valproate were introduced following a European-wide review of the latest evidence on harms from valproate exposure during pregnancy, including congenital anomalies and neurodevelopmental disorders including autism in children. These measures include the valproate Pregnancy Prevention Programme, the goal of which is to rapidly reduce and eventually eliminate pregnancies exposed to valproate.<\/p>
<\/p>
The Medicines and Healthcare products Regulatory Agency (MHRA) is monitoring the impact of, and adherence to, the strengthened regulatory recommendations for valproate including the Pregnancy Prevention Programme, using research studies and routinely collected healthcare data. These include data from the Clinical Practice Research Datalink, national databases in England (NHS Business Services Authority and NHS Digital), Scotland (Information Services Division), and Northern Ireland (Health and Social Care Northern Ireland) linking community drug dispensing and maternity services data where these are available. The MHRA is also accessing data on valproate from clinical audits run by healthcare professional organisations, and information on patients\u2019 experience of introduction of the strengthened regulatory measures via surveys conducted by charitable organisations and patient groups.<\/p>
<\/p>
Monitoring of prescribing of valproate has shown a slow, continued decline in women of childbearing age. Data show variability in levels of prescribing of valproate to women of childbearing age across different clinical commissioning groups in England. The current monitoring methods used by the MHRA do not enable comprehensive monitoring of compliance at the prescriber or patient level. It is therefore not possible to estimate the number of healthcare professionals who are not complying with all aspects of the Pregnancy Prevention Programme. Surveys of patient experiences have shown some evidence of non-compliance amongst healthcare professionals with the valproate Pregnancy Prevention Programme. Actions are being taken by the relevant professional regulators to follow up and address this.<\/p>
<\/p>
The recent European review of valproate in pregnancy considered a possible association between birth defects and persistent developmental disorders associated with paternal valproate treatment at the time of conception. The review concluded that there was insufficient evidence at present to establish such a link. A retrospective observational study is to be undertaken to further investigate this issue for which a study protocol is currently being agreed by the European Medicines Agency.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "232043"}
, {"_value" : "232045"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-03-21T12:14:16.873Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pregnancy: Sodium Valproate"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate he has made on the number of healthcare professionals that are not complying with the requirements of the valproate pregnancy prevention programme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4436", "label" : {"_value" : "Biography information for Cat Smith"}
}
, "tablingMemberConstituency" : {"_value" : "Lancaster and Fleetwood"}
, "tablingMemberPrinted" : [{"_value" : "Cat Smith"}
], "uin" : "232044"}
, {"_about" : "http://data.parliament.uk/resources/1088403", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1088403/answer", "answerText" : {"_value" : "
In April 2018, strengthened regulatory measures for valproate were introduced following a European-wide review of the latest evidence on harms from valproate exposure during pregnancy, including congenital anomalies and neurodevelopmental disorders including autism in children. These measures include the valproate Pregnancy Prevention Programme, the goal of which is to rapidly reduce and eventually eliminate pregnancies exposed to valproate.<\/p>
<\/p>
The Medicines and Healthcare products Regulatory Agency (MHRA) is monitoring the impact of, and adherence to, the strengthened regulatory recommendations for valproate including the Pregnancy Prevention Programme, using research studies and routinely collected healthcare data. These include data from the Clinical Practice Research Datalink, national databases in England (NHS Business Services Authority and NHS Digital), Scotland (Information Services Division), and Northern Ireland (Health and Social Care Northern Ireland) linking community drug dispensing and maternity services data where these are available. The MHRA is also accessing data on valproate from clinical audits run by healthcare professional organisations, and information on patients\u2019 experience of introduction of the strengthened regulatory measures via surveys conducted by charitable organisations and patient groups.<\/p>
<\/p>
Monitoring of prescribing of valproate has shown a slow, continued decline in women of childbearing age. Data show variability in levels of prescribing of valproate to women of childbearing age across different clinical commissioning groups in England. The current monitoring methods used by the MHRA do not enable comprehensive monitoring of compliance at the prescriber or patient level. It is therefore not possible to estimate the number of healthcare professionals who are not complying with all aspects of the Pregnancy Prevention Programme. Surveys of patient experiences have shown some evidence of non-compliance amongst healthcare professionals with the valproate Pregnancy Prevention Programme. Actions are being taken by the relevant professional regulators to follow up and address this.<\/p>
<\/p>
The recent European review of valproate in pregnancy considered a possible association between birth defects and persistent developmental disorders associated with paternal valproate treatment at the time of conception. The review concluded that there was insufficient evidence at present to establish such a link. A retrospective observational study is to be undertaken to further investigate this issue for which a study protocol is currently being agreed by the European Medicines Agency.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-03-21", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "232043"}
, {"_value" : "232044"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-03-21T12:14:16.92Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pregnancy: Sodium Valproate"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of link between birth defects and persistent developmental disorders and fathers taking valproate at the time of conception.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4436", "label" : {"_value" : "Biography information for Cat Smith"}
}
, "tablingMemberConstituency" : {"_value" : "Lancaster and Fleetwood"}
, "tablingMemberPrinted" : [{"_value" : "Cat Smith"}
], "uin" : "232045"}
], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-ddpCreated=2019-03-13T22%3A03%3A23.100Z&houseId=1&answeringDeptId=17&min-ddpCreated=2018-12-05T21%3A54%3A01.503Z", "page" : 0, "startIndex" : 1, "totalResults" : 2013, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}